About DeveloGen
DeveloGen is a Healthcare company based in Gottingen (Germany) founded in 1996, and was acquired by Evotec in July 2010. It operates as a novel therapeutics are discovered for metabolic and endocrine disorders. DeveloGen has raised $74.58 million across 7 funding rounds from investors including Evotec, Commerzbank and Nomura. DeveloGen has completed 1 acquisition, including Peptor. DeveloGen offers products and services including Antibodies, Assay Kits, Elisa Kits, DNA Tools, and PCR Kits. Its focus areas include Life Sciences, Diabetes and Drugs. Its competitors include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Discovery of novel therapeutics for the treatment of metabolic and endocrine disorders. The most advanced lead, DG770, triggers beta cell proliferation and neogenesis and had demonstrated efficacy and safety in various preclinical models. The company also had an integrated discovery alliance with Boehringer Ingelheim on small molecules to treat insulin resistance (type 2 diabetes) and a development partnership with Andromeda (Teva) on DiaPep277, a synthetic peptide immunomodulator to treat type 1 diabetes.
- Headquarters Gottingen, Germany
- Stage Acquired
- SectorsHealthcare
- Website develogen.com
- Social LinkedIn
- Acquired by Evotec (Jul 2010)
Products & Services of DeveloGen
DeveloGen offers a comprehensive portfolio of products and services, including Antibodies, Assay Kits, Elisa Kits, DNA Tools, and PCR Kits.
Tools for detecting proteins in scientific experiments.
Kits for performing assays in laboratory research.
Kits for enzyme-linked immunosorbent assays in analysis.
Products for DNA processing and genomic studies.
Kits for polymerase chain reaction in research.
Funding Insights of DeveloGen
DeveloGen has successfully raised a total of $74.58M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $500 thousand completed in February 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.58M
- Total Rounds 7
- Last Round Grant — $500,000
- First Round $13.5M
(Jul 1996)
- Investors Count 10
All 7 funding rounds of DeveloGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2010 | $500,000 | Grant | – | – | |
| Jul 2006 | $607,349 | Grant | – | – | – |
| Jan 2006 | – | Grant | – | – | |
| Oct 2005 | $22.8M | Series C | – | – | |
| Apr 2001 | $35.28M | Series B | – | – | |
| Jan 1998 | $3M | Series A | – | – | |
| Jul 1996 | $13.5M | Series A | – | – | – |
11 investors in total: 11 institutional.
Investors in DeveloGen
DeveloGen has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Evotec, Commerzbank and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is invested in life science innovations for healthcare transformation. | – | tvm-capital.com | Munich, Germany | |
Early & late stage life sciences focused VC firm funding companies in the US and Europe | – | global-life-science-ventures.com | Munich, Germany | |
- | – | dankap.dk | - | |
- | – | jdrf.org | - | |
- | – | dvcg.de | - | |
Diversified asset management services are offered globally by the firm. | 1925 | nomura.com | Chuo City, Japan | |
- | – | imhventure.de | - | |
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
- | – | drkw.com | - | |
Commercial banking services are offered to corporate and retail clients. | 1870 | commerzbank.com | Frankfurt, Germany |
Investor details for DeveloGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DeveloGen
DeveloGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Peptor.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Protein therapeutics for diabetes and immune diseases were developed. | peptor.de | Rehovot, Israel | 1993 | Nov 2003 | •••• |
Complete acquisition details for DeveloGen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of DeveloGen
Competitors of DeveloGen
DeveloGen has 9 listed competitors in our database, 8 of them funded. They include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| ganlee.com | 1988 | Beijing, China | $46.46M | – | Insulin analogs and medical devices are developed and commercialized. |
Detailed competitors of DeveloGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as DeveloGen (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DeveloGen
DeveloGen was founded in 1996.
DeveloGen is headquartered in Gottingen, Germany. It is registered at Gottingen, Niedersachsen, Germany.
DeveloGen is a funded company, having raised a total of $74.58M across 7 funding rounds to date. The company's 1st funding round was a Series A of $13.5M, raised on Jul 1996.
Discovery of novel therapeutics for the treatment of metabolic and endocrine disorders. The most advanced lead, DG770, triggers beta cell proliferation and neogenesis and had demonstrated efficacy and safety in various preclinical models. The company also had an integrated discovery alliance with Boehringer Ingelheim on small molecules to treat insulin resistance (type 2 diabetes) and a development partnership with Andromeda (Teva) on DiaPep277, a synthetic peptide immunomodulator to treat type 1 diabetes.
DeveloGen's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
DeveloGen offers Antibodies, Assay Kits, Elisa Kits, DNA Tools, and PCR Kits.
DeveloGen has made 1 acquisition, including Peptor.
DeveloGen has 11 investors. Key investors include Evotec, Commerzbank, Nomura, KfW, and JDRF.
Yes. DeveloGen was acquired by Evotec in July 2010.